These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2569924)

  • 1. An immunologic profile of young adults with head and neck cancer.
    Schantz SP; Liu FJ
    Cancer; 1989 Sep; 64(6):1232-7. PubMed ID: 2569924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The relationship of circulating IgA to cellular immunity in head and neck cancer patients.
    Schantz SP; Liu FJ; Taylor D; Beddingfield N; Weber RS
    Laryngoscope; 1988 Jun; 98(6 Pt 1):671-8. PubMed ID: 3259661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic determinants of head and neck cancer response to induction chemotherapy.
    Schantz SP; Savage HE; Racz T; Liu FJ; Brown BW; Rossen RD; Hong WK
    J Clin Oncol; 1989 Jul; 7(7):857-64. PubMed ID: 2472470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total lymphocyte and T lymphocyte subpopulation levels in head and neck squamous cell carcinomas.
    Soysal V; Yigitbasi OG; Alper M; Patiroglu T; Güney E
    J Exp Clin Cancer Res; 1998 Jun; 17(2):207-12. PubMed ID: 9700582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunologic evaluation and prognosis in patients with head and neck cancer.
    Hilal EY; Wanebo HJ; Pinsky CM; Middleman P; Strong EW; Oettgen HF
    Am J Surg; 1977 Oct; 134(4):468-73. PubMed ID: 303057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell surface markers for T and B lymphocytes activation and adhesion as putative prognostic biomarkers for head and neck squamous cell carcinoma.
    Andrade MC; Ferreira SB; Gonçalves LC; De-Paula AM; de Faria ES; Teixeira-Carvalho A; Martins-Filho OA
    Hum Immunol; 2013 Dec; 74(12):1563-74. PubMed ID: 23994583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of preoperative immunologic test results with recurrence in patients with head and neck cancer.
    Ryan RE; Neel HB; Ritts RE
    Otolaryngol Head Neck Surg (1979); 1980; 88(1):58-63. PubMed ID: 6967203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of lymphocyte subsets and natural killer cells in head and neck cancers. An immunohistological study using monoclonal antibodies.
    Harabuchi Y; Yamanaka N; Kataura A
    Arch Otorhinolaryngol; 1985; 242(1):89-97. PubMed ID: 3899069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
    Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
    Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Major immunoglobulin ratios in carcinoma of the head and neck.
    Katz AE; Nysather JO; Harker LA
    Ann Otol Rhinol Laryngol; 1978; 87(3 Pt 1):412-5. PubMed ID: 655583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell subsets and natural killer cell function with squamous cell carcinoma of the head and neck.
    Strome M; Clark JR; Fried MP; Rodliff S; Blazar BA
    Arch Otolaryngol Head Neck Surg; 1987 Oct; 113(10):1090-3. PubMed ID: 3497652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of subsets of lymphocytes infiltrating head and neck tumor tissue: a preliminary report.
    Rabin BS; Johnson J; Claassen D
    Laryngoscope; 1984 May; 94(5 Pt 1):688-90. PubMed ID: 6232437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
    Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
    J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon activity and its characterization in the sera of patients with head and neck cancer.
    Sato M; Yoshida H; Yanagawa T; Yura Y; Urata M; Atsumi M; Furumoto N; Hayashi Y; Takegawa Y
    Cancer; 1984 Oct; 54(7):1239-51. PubMed ID: 6205740
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer.
    Schantz SP; Brown BW; Lira E; Taylor DL; Beddingfield N
    Cancer Immunol Immunother; 1987; 25(2):141-8. PubMed ID: 3499224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunobiologic staging of patients with carcinoma of the head and neck.
    Katz AE
    Laryngoscope; 1983 Apr; 93(4):445-63. PubMed ID: 6339850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Illness stage and IgA-anti-Fab/F(ab')2 autoantibody activity in serum of patients with malignant head-neck tumors].
    Lorenz KJ; Süsal C; Opelz G; Maier H
    Laryngorhinootologie; 1996 Dec; 75(12):764-8. PubMed ID: 9081283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck.
    Neuchrist C; Kornfehl J; Grasl M; Lassmann H; Kraft D; Ehrenberger K; Scheiner O
    Int Arch Allergy Immunol; 1994 May; 104(1):97-100. PubMed ID: 7950411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum immunoglobulin levels in patients with head and neck cancer (IgE, IgA, IgM, IgG).
    Vinzenz K; Pavelka R; Schönthal E; Zekert F
    Oncology; 1986; 43(5):316-22. PubMed ID: 3763126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma.
    Wolf GT; Carey TE
    J Natl Cancer Inst Monogr; 1992; (13):67-74. PubMed ID: 1389697
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.